RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia.
about
RAS mutations in early age leukaemia modulated by NQO1 rs1800566 (C609T) are associated with second-hand smoking exposures.RAS oncogenes: weaving a tumorigenic webGrowth inhibitory effect of wild-type Kras2 gene on a colonic adenocarcinoma cell line.Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia.Backtracking RAS mutations in high hyperdiploid childhood acute lymphoblastic leukemia.Ras in cancer and developmental diseasesRas pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibitionHigh-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling.Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias.Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotypeTargeting oncogenic Ras signaling in hematologic malignancies.Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trialLeukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia.BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitorsK-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemiaRoles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic TargetingThe pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia.Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma.Current status and future directions of T-lymphoblastic lymphoma in children and adolescents.Aberrant expression of RasGRP1 cooperates with gain-of-function NOTCH1 mutations in T-cell leukemogenesis.Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes.Tobacco Smoke and Ras Mutations Among Latino and Non-Latino Children with Acute Lymphoblastic Leukemia.Genetic mutational profiling analysis of T cell acute lymphoblastic leukemia reveal mutant FBXW7 as a prognostic indicator for inferior survival.Analysis of KRAS and NRAS Gene Mutations in Arab Asian Children With Acute Leukemia: High Frequency of RAS Mutations in Acute Lymphoblastic Leukemia.Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic Leukemia.High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia.RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia.Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia.RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia.Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia.The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia.Inhibition of the NEDD8 conjugation pathway induces calcium-dependent compensatory activation of the pro-survival MEK/ERK pathway in acute lymphoblastic leukemia.New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update.Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia.Impact of mutations in FLT3, PTPN11 and RAS genes on the overall survival of pediatric B cell precursor acute lymphoblastic leukemia in Brazil.
P2860
Q27852887-C27AD726-884F-468D-ACF1-75CDA74BB03FQ28250360-E0967312-FBB1-46A1-B7E6-2680BB565436Q33787772-48712269-79E6-4884-878E-3D43C04DD01CQ34052520-C5C75FC6-4304-4A60-889B-7F2930858851Q34143049-7743DA65-2CB7-49F3-9756-26BD75A94524Q34202697-03B31F8D-B6DB-4E82-8267-B445FEF34000Q34580110-A30CF056-8F9E-425F-8439-7A8295D191B1Q35208383-6312A85A-4435-41F4-9CA0-68EDF4EF9859Q35220417-09B91A96-9D8C-4C01-995E-1D6C530A0C0DQ36105608-F61A4ED1-6287-4047-870B-C2A4705682E9Q36273532-C4ADF141-5C82-4527-9F6F-EB3F36968893Q36352506-F0C387FB-73AB-484B-AE3A-450931DA8D31Q36442504-6269E766-913B-4C59-A121-61D0FD9B48E1Q36800426-0B035786-25A8-444C-BEB6-64FC7CC968C2Q36866417-9E747E18-BF75-433A-AE16-F786A8DE2F6DQ36941105-98C359F6-F0A3-40DE-9B5F-24EAE8099F6CQ36947793-49F83AFC-8AA0-4125-B234-0338F6EDE62CQ37268926-1538A960-3E76-4468-A733-33226D3379C0Q37865381-0239C4B3-A4B1-4DEE-8C2E-628F15F8807FQ38227885-FD4D66FB-01D6-41B5-B76D-5E1590F46FD4Q38460308-24730B7A-DCFA-4E8D-AB98-9ADBFBEB7E69Q38771110-03E474A8-BD27-40BD-86DB-18405C6B9601Q38779952-A012CAB5-A49D-4731-9CEF-9F47EE19A423Q39437389-ECD12AF7-9A94-4283-87D8-A7200CD856B3Q39992854-0F1A1BF6-C406-45B8-A64A-FD18D3E5C2AFQ40213288-B91E6423-64D4-4183-BBDE-13BB8FD74DEAQ41407670-237E90E4-ADD1-41A9-A52B-79B7B4878AC9Q41535044-533C4A2B-8A30-485D-BC54-4ECC5FD6CC49Q41660964-4549902A-FFE6-45EF-9447-FCDEF5BF01F7Q42733616-67EA6F9A-6224-4AC4-BBD3-882035D9384AQ46519927-D692DC13-40EC-425E-B539-AC8BD2786408Q46799049-2B9CF332-C105-4779-9929-2582934D4B3CQ47875530-5F43F2AD-711D-4139-BDC6-A52C1617B2EEQ47884832-7FA777DB-37EA-4F3C-8446-1C42F15E4977Q48153742-F6956A2C-301D-49FB-BC10-64E2A3B0DA73Q48188689-22876B44-052C-495C-B4CE-27A65571CA06Q49787961-2A0E8256-1EC7-46C1-BF22-652A615D7FD2Q52593673-E11894BA-C00A-42BB-94C5-A2263AFAC4E0Q53796172-EF88F48A-CE81-4F0A-987A-ACC3B3138FA6Q54406965-EE7E7568-B7DD-4898-96D0-013B7E3B203C
P2860
RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia.
@en
RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia.
@nl
type
label
RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia.
@en
RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia.
@nl
prefLabel
RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia.
@en
RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia.
@nl
P2093
P2860
P356
P1433
P1476
RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia
@en
P2093
H N Sather
J Envall-Fox
J P Perentesis
L L Robison
M Steinbuch
W Kiffmeyer
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403272
P577
2004-04-01T00:00:00Z